ZNF154 and cancer: This further confirms the utility of leveraging heterogeneous methylation data to improve the performance of ZNF154 and demonstrates that EpiClass derived optimal cutoffs for a given locus are consistent not only across different sample cohorts but also across different cancer types and stages of disease.